Cite
HARVARD Citation
Murakami, S. et al. (n.d.). Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, suppresses the progression of atherosclerosis in diabetic apoE-deficient mice. Diabetes research and clinical practice. pp. S99-. [Online].